Literature DB >> 28480928

Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.

Zeynab Fakhar1, Thavendran Govender1, Glenn E M Maguire2, Gyanu Lamichhane3, Ross C Walker4, Hendrik G Kruger1, Bahareh Honarparvar1.   

Abstract

Despite the advances in tuberculosis treatment, TB is still one the most deadly infectious diseases and remains a major global health quandary. Mycobacterium tuberculosis (Mtb) is the only known mycobacterium with a high content of 3→3 crosslinks in the biosynthesis of peptidoglycan, which is negligible in most bacterial species. An Mtb lacking LdtMt2 leads to alteration of the colony morphology and loss of virulence which makes this enzyme an attractive target. Regardless of the vital role of LdtMt2 for cell wall survival, the impact of ligand binding on the dynamics of the β-hairpin flap is still unknown. Understanding the structural and dynamical behaviour of the flap regions provides clear insight into the design of the effective inhibitors against LdtMt2. Carbapenems, an specific class of β-lactam family, have been shown to inactivate this enzyme. Herein a comprehensive investigation of the flap dynamics of LdtMt2 complex with substrate and three carbapenems namely, ertapenem, imipenem and meropenem is discussed and analyzed for the first account using 140 ns molecular dynamics simulations. The structural features (RMSD, RMSF and Rg) derived by MD trajectories were analyzed. Distance analysis, particularly tip-tip SER135-ASN167 index, identified conformational changes in terms of flap opening and closure within binding process. Principal component analysis (PCA) was employed to qualitatively understand the divergent effects of different inhibitors on the dominant motion of each residue. To probe different internal dynamics induced by ligand binding, dynamic cross-correlation marix (DCCM) analysis was used. The binding free energies of the selected complexes were assessed using MM-GBSA method and per residue free energy decomposition analysis were performed to characterize the contribution of the key residues to the total binding free energies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28480928     DOI: 10.1039/c7mb00110j

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  12 in total

1.  Molecular insight on the non-covalent interactions between carbapenems and L,D-transpeptidase 2 from Mycobacterium tuberculosis: ONIOM study.

Authors:  Thandokuhle Ntombela; Zeynab Fakhar; Collins U Ibeji; Thavendran Govender; Glenn E M Maguire; Gyanu Lamichhane; Hendrik G Kruger; Bahareh Honarparvar
Journal:  J Comput Aided Mol Des       Date:  2018-05-29       Impact factor: 3.686

2.  Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations.

Authors:  Victor T Sabe; Gideon F Tolufashe; Collins U Ibeji; Sibusiso B Maseko; Thavendran Govender; Glenn E M Maguire; Gyanu Lamichhane; Bahareh Honarparvar; Hendrik G Kruger
Journal:  J Mol Model       Date:  2019-10-28       Impact factor: 1.810

3.  Targeting ebola virus VP40 protein through novel inhibitors: exploring the structural and dynamic perspectives on molecular landscapes.

Authors:  Shama Khan; Zeynab Fakhar; Aijaz Ahmad
Journal:  J Mol Model       Date:  2021-01-25       Impact factor: 1.810

4.  Multi-catalytic Sites Inhibition of Bcl2 Induces Expanding of Hydrophobic Groove: A New Avenue Towards Waldenström Macroglobulinemia Therapy.

Authors:  Ghazi Elamin; Aimen Aljoundi; Mahmoud E S Soliman
Journal:  Protein J       Date:  2022-03-02       Impact factor: 2.371

5.  Allosteric cooperation in β-lactam binding to a non-classical transpeptidase.

Authors:  Nazia Ahmad; Sanmati Dugad; Varsha Chauhan; Shubbir Ahmed; Kunal Sharma; Sangita Kachhap; Rana Zaidi; William R Bishai; Gyanu Lamichhane; Pankaj Kumar
Journal:  Elife       Date:  2022-04-27       Impact factor: 8.713

6.  Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.

Authors:  Pankaj Kumar; Varsha Chauhan; José Rogério A Silva; Jerônimo Lameira; Felipe B d'Andrea; Shao-Gang Li; Stephan L Ginell; Joel S Freundlich; Cláudio Nahum Alves; Scott Bailey; Keira A Cohen; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

7.  Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation.

Authors:  Liang-Chang Hu; Chuan-Hua Ding; Hong-Ying Li; Zhen-Zhen Li; Ying Chen; Li-Peng Li; Wan-Zhong Li; Wen-Shan Liu
Journal:  J Food Biochem       Date:  2022-02-06       Impact factor: 2.720

8.  Structural insight into YcbB-mediated beta-lactam resistance in Escherichia coli.

Authors:  Nathanael A Caveney; Guillermo Caballero; Henri Voedts; Ana Niciforovic; Liam J Worrall; Marija Vuckovic; Matthieu Fonvielle; Jean-Emmanuel Hugonnet; Michel Arthur; Natalie C J Strynadka
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919

Review 9.  In Silico Strategies in Tuberculosis Drug Discovery.

Authors:  Stephani Joy Y Macalino; Junie B Billones; Voltaire G Organo; Maria Constancia O Carrillo
Journal:  Molecules       Date:  2020-02-04       Impact factor: 4.411

10.  ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.

Authors:  Zeynab Fakhar; Shama Khan; Suliman Y AlOmar; Afrah Alkhuriji; Aijaz Ahmad
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.